Abstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based on prevention of the inactivation process of bioactive peptides, the most important in the context of treatment of diabetes of which is glucagon-like peptide-1 (GLP-1). Most clinical experience with DPP-4 inhibition is based on vildagliptin (Galvus R , Novartis) and sitagliptin (Januvia R , Merck). These compounds improve glycemic control both in monotherapy and in combination with other oral hyperglycemic agents. Both have also been shown to effi ciently improve glycemic control when added to ongoing metformin therapy in patients with inadequate glycemic control. Under that condition, they reduce HbA 1c levels by 0.65%-1.1% (baseline HbA 1c 7.2-8.7%) in studies up to 52 weeks of duration in combination versus continuous therapy with metformin alone. Sitagliptin has also been examined in initial combination therapy with metformin have; HbA 1c was reduced by this combination by 2.1% (baseline HbA 1c 8.8%) after 24 weeks of treatment. Both fasting and prandial glucose are reduced by DPP-4 inhibition in combination with metformin in association with improvement of insulin secretion and insulin resistance and increase in concentrations of active GLP-1. The combination of DPP-4 inhibition and metformin has been shown to be highly tolerable with very low risk of hypoglycemia. Hence, DPP-4 inhibition in combination with metformin is an effi cient, safe and tolerable combination therapy for type 2 diabetes.
Introduction
It is known that both the level and the duration of hyperglycemia in type 2 diabetes are closely related to the risk of developing diabetic complications (Stratton et al 2000) . Therefore, achieving glycemic control is a prerequisite for prevention of cardiovascular and microvascular complications in type 2 diabetes. Lifestyle interventions, including dietary adjustments and increased physical activity, are cornerstones of the therapy. For most patients, however, pharmacological intervention is required and present guidelines suggest metformin to be a fi rst line treatment (Inzucchi 2000; Nathan et al 2006) . Metformin is an inexpensive compound with documented glucose-lowering effect in both obese and non-obese subjects with type 2 diabetes (Inzucchi 2002; Hundal and Inzucchi 2003; Setter et al 2003; Consoli et al 2004; Donnelly et al 2006) . Metformin reduces glycemic levels primarily by inhibiting hepatic glucose output (Bailey and Turner 1996; Leverve et al 2003; Stumvoll et al 1995) . Metformin has also been shown to improve insu lin sensitivity in liver and muscle (Ginnarelli et al 2003) . Additional suggested mechanistic effects of metformin are inhibition of glucose absorption in the gut (Ikeda et al 2000) and increase in plasma levels of GLP-1 (Mannucci et al 2001) . As has been reviewed (Bailey and Turner 1996) , metformin reduces HbA 1c levels in the range of 1%-1.5%, depending on the baseline HbA 1c levels and the compound is well tolerated, although gastrointestinal adverse events are quite common during the initiation of the therapy. Hypoglycemia is rarely seen during metformin therapy, and the Ahrén potential fatal adverse event of lactic acidosis is uncommon; nevertheless cautious should always be exercised when treating subjects with renal insuffi ciency with metformin.
Add-on treatment to metformin often required
In spite of the benefi cial effects of metformin in improving glycemic control, very often, however, metformin alone is insuffi cient for achievement of good metabolic control. Often, also, glycemic control deteriorates in metformintreated patients. This necessitates combination therapy by adding a secondary compound to metformin. Most often, sulphonylureas are added (Inzucchi 2002; Nathan et al 2006) . The rationale for this combination is that sulphonylureas stimulate insulin secretion, which is a complimentary mechanism to the improvement in insulin sensitivity by metformin. Other combinations with metformin include thiazolidinediones and insulin (Hundal and Inzucchi 2003; Setter et al 2003; Charbonnel et al 2005; Derosa et al 2006; Umpierrez et al 2006) . However, the combinations with sulphonylureas and thiazolidinediones have faced problems, in that sulphonylureas increase the risk of hypoglycemia (Del Prato and Pulizzi 2006; Green and Feinglos 2007) and thiazolidinediones result in weight gain and potential problems of cardiovascular adverse events and increase in the risk of bone fractures in women (Kahn et al 2006; Levetran 2007; Nissen and Wolski 2007) . Also the novel GLP-1 based therapy has been found to be successful in combination with metformin. This applies both to the strategy of activating the GLP-1 receptors by exenatide (DeFronzo et al 2005) or liraglutide (Feinglos et al 2005) , and by the strategy of preventing the inactivation of endogenous GLP-1 by inhibiting dipeptidyl peptidase-4 (DPP-4) (Ahrén et al 2004; Charbonnel et al 2006; Bosi et al 2007; Brazg et al 2007; Goldstein et al 2007) . This review summarizes the experience of combining metformin and a DPP-4 inhibitor in the treatment.
GLP-1 as a target for treatment of type 2 diabetes
The rationale for the development of DPP-4 inhibition in the treatment of type 2 diabetes relies on augmentation of the incretin effect (Holst and Deacon 1998) . The incretin effect is the exaggerated insulin secretion that follows oral glucose administration when compared to intravenous glucose administration and it is attributed to gut hormones augmenting glucose-stimulated insulin secretion (Drucker and Nauck 2006) . The two most important incretin hormones are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) (Drucker and Nauck 2006) . GLP-1 is produced in L-cells, which are located mainly in the distal portion of the ileum. GLP-1 is released during meal ingestion and stimulates insulin secretion in a glucosedependent manner (Drucker and Nauck 2006) . GLP-1 also inhibits glucagon secretion (Dunning et al 2005) , delays gastric emptying (Nauck et al 1997) and induces satiety (Gutzwiller et al 1999) . In addition, animal studies have presented evidence that GLP-1 increases beta cell mass by stimulating proliferation and inhibiting apoptosis (Perfetti and Hui 2004) , although it should be emphasized that such an effect has not been demonstrated in humans. Because all these effects would be important in the treatment of type 2 diabetes, GLP-1 has been developed as a novel therapy (Ahrén and Schmitz 2004) . The development of GLP-1 as a therapy has, however, been complicated by its rapid inactivation, which is due to removal of the N-terminal dipeptide end through DPP-4, which inactivates GLP-1 (Mentlein 1999) . To overcome this, two strategies have been used. One strategy is the development of GLP-1 receptor agonists (GLP-1 mimetics such as exenatide and liraglutide), which are resistant to DPP-4 (Ahrén and Schmitz 2004) . The other strategy is the development of inhibitors of DPP-4, which prevent the inactivation of GLP-1 and thereby enhance and prolong the action of the endogenous incretin hormone (Ahrén and Schmitz 2004; Mari et al 2005; Ahrén 2007a Ahrén , 2007b . DPP-4 inhibition also prevents the inactivation of the other incretin hormone, GIP, and therefore the concentrations of the active form also of this hormone are increased during DPP-4 inhibition (Mari et al 2005) . However, since the action of GIP to stimulate insulin secretion is almost entirely lost in type 2 diabetes (Vilsbøll et al 2002) , this raise of GIP concentrations is of less importance.
DPP-4 inhibition as a target for treatment of type 2 diabetes
The rational of DPP-4 inhibition for the treatment of type 2 diabetes was outlined already in 1998 (Holst and Deacon 1998) . The fi rst proof-of-concept study of DPP-4 inhibition showed improved meta bolic control with reduced fasting and prandial glucose levels and reduction of HbA 1c after 4 weeks of treatment of the DPP-4 inhibitor, NVP-DPP728 (Ahrén et al 2002) . Improved glycemic control by DPP-4 inhibition has been confi rmed in many studies with other compounds and today several DPP-4 inhibitors are in the progress of development (Ahrén 2007a (Ahrén , 2007b . Most experience exists for vil dagliptin (LAF237, Galvus R , Novartis) and sitagliptin (MK-0431, Januvia R , Merck), which are orally active DPP-4 inhibition plus metformin in the treatment of type 2 diabetes compounds, which effi ciently inhibit DPP-4 activity (Ahrén 2006; Kim et al 2005) . Both compounds inhibit plasma DPP-4 activity for more than 16 hours after a single administration and are therefore both possible to administer once daily. Furthermore, they have both been shown to improve glycemic control when used in monotherapy as well as in combination therapy with metformin and thiazodilidinedione (Ahrén 2006; Deacon 2007; Gallwitz 2007) . Sitagliptin has been approved for treatment of type 2 diabetes in the US and in Europe in combination with metformin and vildagliptin has been approved for treatment of type 2 diabetes in Europe. Of particular importance is that DPP-4 inhibitors are safe and tolerable and that this in combination with their effi ciency allow them to be used in early stages of the disease. One such early indication would be to use DPP-4 inhibitors in combination with metformin.
Rationale for combining metformin with DPP-4 inhibition
Type 2 diabetes develops when insulin secretion is insuffi ciently raised to match insulin resistance (Kahn 2001; DeFronzo 2004 ). In addition, glucagon levels are inappropriately elevated, which enhances hepatic glucose output and increases fasting glucose (Dunning et al 2005) . Therefore, diabetes is a disease with at least three main defects, which need to be corrected: impaired insulin secretion, insulin resistance and hypersecretion of glucagon. The rationale for combining metformin with DPP-4 inhibitors is the complimentary mechanism of action of the two strategies. Thus, metformin acts primarily by reducing hepatic glucose output and improving insulin sensitivity in liver and muscle (Stumvoll et al 1995; Bailey and Turner 1996; Hundal and Inzucchi 2003; Leverve et al 2003; Setter 2003) whereas DPP-4 inhibitors act by increasing GLP-1 levels and thereby stimulating insulin secretion and inhibiting glucagon secretion (Ahrén 2007a; Ahrén 2007b ). The two strategies therefore have the potential to improve different mechanisms, which are defective in type 2 diabetes and therefore an additive or synergistic action when used in combination is anticipated. In addition, metformin has been shown to increase GLP-1 levels (Mannucci et al 2001) , which would be a potential for an additional synergistic ac tion with DPP-4 inhibitors. The mechanism underlying the increase in GLP-1 levels by metformin remains to be fi nally established; it has been suggested to be caused by inhibition of DPP-4 (Lindsay et al 2005; Mannucci et al 2001) , although there are also fi ndings that metformin does not affect DPP-4 activity (Hinke et al 2002) . Instead, more recent fi ndings suggest that metformin stimulates the secretion of GLP-1 from the gut (Migoya et al 2007) . Hence, from a mechanistic point of view, there is a clear rationale for combining metformin with DPP-4 inhibitors. Another important information is that the pharmacokinetics of metformin and a DPP-4 inhibitor do not change by combining the two, as shown for sitagliptin, which further indicates the feasibility of the combination (Herman et al 2006) .
Vildagliptin and sitagliptin as monotherapy
Both vildagliptin and sitagliptin reduce fasting and prandial glucose as well as HbA 1c when used in monotherapy for the treatment of type 2 diabetes; HbA 1c has been shown to be reduced by these compounds by 0.65%-1.1% after study periods of 3-12 months from baseline levels of 7.2%-8.7% ( . Furthermore, these studies have shown that both vildagliptin and sitagliptin are safe and tolerable with incidences of adverse events not different from what is seen after placebo treatment and that there is a very low rate of hypoglycemia during the treatment with the DPP-4 inhibitors. Recent reviews have summarized these monotherapy studies in more detail (Ahrén 2007a (Ahrén , 2007b .
DPP-4 inhibition as add-on therapy to metformin
Several studies have reported the experience of treatment with a DPP-4 inhibitor in combina tion with metformin. The fi rst combination study was a 52 week trial, in which vildagliptin at 50 mg daily or placebo was added to ongoing treatment with metformin (1.5-3 g daily) in patients with a mean baseline HbA 1c of 7.8% (Ahrén et al 2004a) . The patients had a mean diabetes duration of 5.5 years and they had been on metformin treatment for 29 months as a mean. The results are illustrated in Figure 1 and show that following the ini tial 12 week study period, HbA 1c was reduced by 0.7% by vildagliptin in combination with metformin compared to metformin alone. After the fi rst 12 weeks of study, patients were followed for another 40 weeks. During this period, HbA 1c increased by 0.066%/month in patients given metformin alone versus only by 0.013%/month after vildagliptin plus metformin.
The between-group difference in change of HbA 1c after 52 week of treatment was 1.1%, showing a clinically important improvement of the glycemic control by adding vildagliptin to metformin. Furthermore, fasting glucose was also reduced by vildagliptin in combination with metformin compared to metformin alone. Thus, from a mean baseline fasting glucose of 9.8 mmol/l across all patients, the between-group difference in fasting glucose after 52 weeks of treatment was 1.1 mmol/l. The study therefore suggests that addition of vildagliptin to metformin prevents the deterioration of glycemic control seen in these patients when given metformin alone. The study also shows that the combination of vildagliptin and metformin is safe and highly tolerable with an overall incidence of any adverse event being similar in the two groups. A second study in 416 patients added vildagliptin at 50 mg once or twice daily to on-going treatment with metformin for a study period of 24 weeks (Bosi et al 2007) . The patients in this study had a mean diabetes duration of 6 years and had been treated with met formin for a mean of 16 months, their mean daily metformin dose was 2.1 g (inclusion criteria Ͼ1.5 g daily). They had a mean baseline HbA 1c was 8.4%. Figure 2 shows the HbA 1c levels in this study. It is seen that HbA 1c was reduced by 0.5% in patients given vildagliptin at 50 mg daily and 0.9% in patients given vildagliptin at 100 mg daily, both in combination with metformin, versus an increase by 0.2% in patients given placebo with on-going metformin. The placebo-adjusted mean reduction in HbA 1c was therefore 0.7% by vildagliptin at 50 mg and 1.1% by vildagliptin at 100 mg daily. The data were also analysed with respect to how many patients who experienced improved glycemic control or had a deterioration of glycemic control. The analysis revealed that in the group given metformin alone, 35% of patients had a deterioration of glycemic control and 31% had no meaningful change in glycemic control. In contrast, of the patients given vildagliptin at 50 mg in combination with metformin, 38% showed a meaningful improve ment in glycemic control and 29% had a marked improvement in glycemic control (defi ned as reduction in HbA 1c by more than 1%). Also fasting plasma glucose was reduced by vildagliptin in combination with metformin. Baseline fasting glucose was 9.7 mmol/l across all groups. In the group given metformin alone, fasting glucose increased by 0.7 mmol/l and the placebo-adjusted reduction in fasting glucose was 0.8 mmol/l in subjects given vildagliptin at 50 mg daily and 1.7 mmol/l in subjects given vildagliptin at 100 mg in combina tion with metformin. Except for fasting triglycerides, lipid values were not signifi cantly altered in any of the groups. However, fasting triglycerides increased from a mean value of 2.3 mmol/l by 19% in subjects given metformin alone but only by 1% in subjects given vildagliptin at 50 mg in combination with metformin and by 5% in the group given vildagliptin at 100 mg in combination with metformin. Mean body weight was 94 kg as a mean across all study groups and did not change signifi cantly in the subjects given vildagliptin at either 50 or 100 mg daily in combination with metformin, whereas body weight was reduced by 1.0 kg in subjects given metformin alone. Finally, total number of adverse events was not significantly different between the groups; the only difference was a reduction in gastrointestinal ad verse events in the subjects given vildagliptin at 50 mg in combination with metformin (9.6%) versus in those given metformin alone (18.2%). In DPP-4 inhibition plus metformin in the treatment of type 2 diabetes conclusion, this large study showed that vildagliptin is well tolerated when given as add-on to metformin for a study period of 24 weeks and that vildagliptin shows a clinically meaningful improvement in glycemic control as verifi ed by dose-related reductions in HbA 1c and fasting glucose.
The fi rst study on the effect of sitagliptin as add-on therapy to patients with inadequate glycaemic control on metformin monotherapy was a four week study in 28 patients (Brazg et al 2007) . The patients had a mean duration of diabetes of 6.6 years, the mean baseline HbA 1c was 7.7% and the mean fasting plasma glucose was 8.4 mmol/l. The study showed that fasting glucose was reduced by 1.3 mmo/l by sitagliptin in combination with metformin versus only by 0.4 mmol/l by metformin alone. The study also included a 24 hr measurement of glucose after the four week treatment period, and this showed a reduction of glucose by approximately 1-1.5 mmol/l throughout the entire 24 h period. Both fasting and prandial glycemia were reduced by this degree. Furthermore, the number of adverse events was not different when sitagliptin was given in combination with metformin versus when metformin was given alone. Hence, this shortterm study verifi ed the effi cient improvement in glycemic control by the addition of DPP-4 inhibition to on-going metformin therapy in asso ciation with safety and tolerability of the combination therapy.
In a long-term study on the effect of sitagliptin as add-on to metformin in subjects with inadequate glycemic control, sitagliptin (100 mg once daily) was added to metformin (Ͼ1.5 g daily) for 24 weeks (Charbonnel et al 2006) . The study comprised a total of 701 patients who had a mean diabetes duration of 6.2 years, a mean baseline HbA 1c of 8.0% and a mean baseline fasting glucose of 9.5 mmol/l. Figure 3 shows the HbA 1c in this study. It is seen that addition of sitagliptin signifi cantly reduced the HbA 1c levels after the 24 week treatment period. The placebo-subtracted reduction in HbA 1c by sitagliptin was 0.65%. A total of 47% of the patients treated with sitagliptin in combination with metformin reached the target of Ͻ7% in HbA 1c while the target was reached by only 18% of the subjects given metformin alone. Also fasting glucose was reduced by sitagliptin in combination with metformin versus metformin alone; the placebo-subtracted reduction by sitagliptin was 1.4 mmol/l. The study also showed that sitagliptin in combination with metformin slightly, although signifi cantly, reduced total cholesterol and triglycerides, whereas HDL-cholesterol was slightly increased. Body weight was slightly reduced in both groups, with no difference between the groups, and, similarly, the degree of adverse events did not differ between the groups. Hence, this 24 week trial in a large number of patients showed that sitagliptin when added to on-going therapy with metformin effi ciently reduces HbA 1c and fasting glucose in combination of being a safe and highly tolerable combination therapy. Following the end of the 24 week trial, patients who did not receive glycemic rescue medication continued to an extension study. During this exten sion, 387 patients continued with the combination of sitagliptin with metformin throughout a 54 week study period. It was found that the mean HbA 1c remained stable at 7.1% during this entire period and, furthermore, the combination was well tolerated during the period (Karasik et al 2007) . Hence, combination of sitagliptin and metformin produced a durable reduction in HbA 1c .
Another study with sitagliptin the addition of the compound (100 mg once daily) with that of glipizide (dosetitration to a maximal doe of 20 mg daily) to the on-going treatment with metformin (Ͼ1.5 g daily) in a 52 week study comprising a total of 1,172 patients (Nauck et al 2007) . The mean baseline HbA 1c levels was 7.5% and this was reduced by 0.67% both by sitagliptin and by glipizide. The occurrence of hypoglycemia was higher in the group given glipizide (32% of patients exhibited one episode of hypoglycemia) than in the group receiving sitagliptin (5%). Furthermore, the mean body weight in creased by 1.1 kg in the group given glimepiride versus a reduction by 1.5 kg in the group given sitagliptin. Hence, also this study showed a good improvement in glycemic control by the combina tion of a DPP-4 inhibitor with metformin.
Recently, it was also reported that the DPP-4 inhibitor, saxagliptin (Bristol-Myers-Squibb), improved glycemic control when added to metformin (DeFronzo et al 2007) . The study comprised a total of 743 patients with a mean HbA 1c of 8.0% and a mean fast ing glucose of 9.8 mmol/l when treated with metformin alone. Saxagliptin was added at 2.5, 5 or 10 mg daily and the study also included a placebo arm; all patients continued with metformin. It was found that after 24 weeks of treatment, saxagliptin had reduced HbA 1c by 0.7 or 0.8% when adjusted for placebo in the three arms. Fasting glucose was reduced by 0.9-1.1 mmol/l.
As for the other DPP-4 inhibitors, also saxagliptin was safe and tolerable and body weight neutral when added to metformin.
The studies thus presented sofar with DPP-4 inhibitors as add-on therapy to metformin show clinically important improvement in glycemic control. Mean HbA 1c levels are reduced by approximately 0.65%-1% from a baseline of 7.8%-8.4%. Furthermore, the combination is tolerable and safe with similar adverse events profi le as placebo-treated patients given metformin alone.
DPP-4 inhibition and metformin as initial combination therapy
During recent years there has been a discussion of introducing initial combination therapy when pharmacological treatment is required for type 2 diabetes, in order to reach therapeu tic goal at an earlier stage and to avoid or delay subsequent changes in therapy for the maintenance of therapeutic goal. One study has examined the possibility of combining DPP-4 inhibition with metformin as initial combination (Goldstein et al 2007) . The study was a 24-week randomized trial comprising 1,092 patients with type 2 diabetes having a mean baseline HbA 1c value of 8.7% and a mean baseline fasting glucose of 11 mmol/l. The pa tients were assigned to one of six treatment arms with sitagliptin 50 mg + metformin 500 mg twice daily, sitagliptin 50 mg + metformin 1000 mg twice daily, metformin alone at 500 or 1000 twice daily, sitagliptin alone at 100 mg once daily or placebo. The results showed that in all treatment groups, except the placebo group, DPP-4 inhibition plus metformin in the treatment of type 2 diabetes a signifi cant reduction in HbA 1c after the 24 week trial period occurred. The placebo-controlled reduc tion of HbA 1c was in the range of 0.8%-2.1% in the different groups (Figure 4) , and when compar ing monother apy versus the initial combination therapy, it was found that combina tion ther apy produced additive effects of improved glycemic control. Hence, the larg est reduction in HbA 1c (2.1%) was seen in the group given sitagliptin 50 mg + met formin 1000 mg twice daily. Similarly, fasting glucose was additively reduced by the combi nation therapy, and the placebo-adjusted reduction in fasting glucose in the group given sitagliptin 50 mg + metformin 1000 mg twice daily was 3.8 mmol/l. The percent age of subjects in each group who reached the treatment target of HbA 1c Ͻ7.0% was 66% in the group given sitagliptin 50 mg + metformin 1000 mg twice daily versus only 38% in the group given metformin at 1000 mg twice daily alone or 20% in the group given sitagliptin at 100 mg daily alone and only 9% in the placebo group. Hence, the initial combi nation of sitagliptin and metformin effi ciently improved glycemic control over a 24 week study pe riod. The number of adverse events was low and the incidences of gastrointesti nal ad verse events were similar when sitagliptin was added to metformin as when metformin was given alone. Furthermore, the incidence of hypoglycemia was low (0.5%-2.2% in the different actively treated groups) and not signifi cantly different from the placebo group (0.6%). Finally, in regard to body weight, there was a signifi cant reduction in body weight after 24 weeks of treatment in all actively treated groups (0.6-1.3 kg) except in the group given sitagliptin alone as monotherapy.
Mechanisms of improved antidiabetic action by combining DPP-4 inhibitors with metformin
DPP-4 inhibitors have been shown to increase GLP-1 levels both under fasting conditions and following meal ingestion (Ahrén et al 2004b; Mari et al 2005) . Furthermore, DPP-4 inhibition improves islet func tion by stimulating insulin secretion, by improving the glu cose sensitivity of the beta cells, and by inhibiting glucagon secretion from the alpha cells (Balas et al 2007; Dunning et al 2005) . This reduces both fasting and prandial glucose which reduces HbA 1c levels. In contrast to GLP-1, DPP-4 inhibi tion does not seem to inhibit gastric emptying (Vella et al 2007) and it does not reduce body weight ( 
GLP-1 levels
One study has examined the effect of the combination of sitagliptin and metformin on concentrations of active and inactive GLP-1 after meal ingestion following 24 weeks of treatment (Migoya et al 2007) . It was found that both sitagliptin and metformin alone increased the postmeal concentration of active GLP-1. Furthermore, when given in combination, the increase in active GLP-1 was more than additive, suggesting a synergistic action of the two compounds.
Islet effects when DPP-4 inhibition is added to metformin
In the initial study on the add-on of vildagliptin to metformin treatment, in which vildagliptin and metformin in combina tion was compared with metformin alone for 52 weeks (Ahrén et al 2004a) , a standardized break fast meal comprising of 465 kcal was served at baseline and after 12, 24 and 52 weeks of treatment. The study evaluated insulin secretion by calculating the suprabasal 30 min area under the C-peptide curve divided by the 30 min increase in glucose after meal ingestion . It was found that glucose tolerance was improved by the combination therapy versus metformin alone. Thus, the mean between-group difference in AUC glu cose was 256 mmol/240 min compared to a baseline of 545 mmol/240 min. Further more, insulin secretion increased gradually during the fi rst 24 weeks by the combina tion therapy and thereafter remained stable for the remaining period of the study ( Figure 5 ). This shows that the combination of vildagliptin with metformin improves beta cell function. The same study also evaluated insulin sensitivity after meal inges tion by calculating the OGIS index (oral glucose insulin sensitivity index). This is a vali dated index which is based on a model of glucose clearance in relation to meal-derived insulin data (Mari et al 2001) . It was found that OGIS gradually increased by the combination therapy ( Figure 5 ). The combined estimation of insulin secretion and insulin sensitivity allowed the estimation of the adaptation index (the product of insulin secretion and sensitivity); the adaptation index gives a fi gure of the ability of the beta-cell to adapt insu lin secretion to the ambient insulin sensitivity (Ahrén and Pacini 1997) . It was found (see also Figure 5 ) that the adaptation index increased by the combination of vildagliptin and metformin versus metformin alone. This change in adaptation index across the entire study group showed a negative correlation with the change in HbA 1c (r = −0.39, p = 0.004) (see Figure 5) . Hence, this analysis of potential mechanisms of action underlying the im proved glycemic control by the combination of vildagliptin and metformin versus metformin alone showed a marked improvement in beta cell function and a slight improvement in insulin sensitivity which together results in improved beta cell adaptation ability to insulin resistance, a measure that correlated to the reduction in HbA 1c . Furthermore, from this study, also baseline and prandial proinsulin levels have been carefully analyzed, and the results have shown a reduction in proinsulin levels in subjects given vildagliptin and metformin in combination versus metformin alone (Ahrén et al 2007) , which further adds to the conclusion that vildagliptin improves beta cell func tion when added to metformin in subjects with type 2 diabetes.
Another study has examined glucose tolerance and indirect markers of beta cell function after meal ingestion following 24 weeks of addition of vildagliptin at 50 or 100 mg daily DPP-4 inhibition plus metformin in the treatment of type 2 diabetes to on-going metformin (Ͼ1.5 g daily) (Bosi et al 2007) . A standard breakfast consisting of 500 kcal was served after the 24 week treatment. Glucose tolerance was determined by prandial glucose levels. Insulin secretion was evaluated by calculating the total 2 h insulin secretion by deconvoluting plasma C-peptide levels and then dividing this fi gure by the area under the 2 h glucose curve. It was found that following the 24 weeks of treatment, subjects given vildagliptin (either 50 or 100 mg daily) in combination with metformin had lower fasting and prandial glucose than subjects given metformin alone. For example, the placebo-adjusted mean 2 hr plasma glucose following meal ingestion was reduced by 1.9 mmol/l by vildagliptin at 50 mg daily and by 2.3 mmol/l by vildagliptin at 100 mg from a baseline of 13.5 mmol/l. Furthermore, beta cell function, was increased in subjects given vildagliptin in combination with metformin versus metformin alone.
Insulin secretion and insulin sensitivity were also determined in the four week study when sitagliptin at 50 mg twice daily was given to on-going metformin therapy (Brazg et al 2007) . Insu lin secretion was evaluated by modeling Cpeptide data after a standardized breakfast meal comprising 765 kcal (Breda and Copbelli 2001) and insulin sensitivity was determined with a composite index, insulin sensitivity index (Matsuda and DeFronzo 1999) . It was found that insulin secretion, as evaluated by this model, was signifi cantly improved after treatment with sitagliptin in combination with metformin versus with metformin alone (Brazg et al 2007) . Furthermore, insulin sensitivity was numerically increased, although this did not reach signifi cance. Finally, the authors also calculated the disposition index, which is insulin secretion (based on insulin levels) times insulin sensitivity, and it was substantially elevated by the combination therapy. Therefore, also this study showed a clear stimulation of insulin secretion by the combination of met formin with a DPP-4 inhibitor.
Beta cell function and insulin sensitivity were as well estimated in the 24 week study with sitagliptin at 100 mg once daily as add-on to metformin (Charbonnel et al 2006) . It was found that after 24 weeks of treatment, along with a reduction in HbA 1c and fasting glucose, the combina tion of sitagliptin and metformin increased fasting insulin and glucose as well as the homeostasis model assessment of β-cell function (HOMA-β, Matthews et al 1985) and the insulin sensitivity marker, quantitative insulin sensitivity check (QUICKI, Katz et al 2000) . Furthermore, the combina tion of sitagliptin and metformin also reduced the proinsulin to insulin ratio under fasting conditions, which is a sign of improved beta cell function. In contrast, in this study, fasting proinsulin levels per se were not altered and the homeostasis model assessment of insulin resistance (HOMA-IR), which is based on the fasting levels of glucose and insulin (Matthews et al 1985) was not altered. Furthermore, in this study, the subjects also received a standardized meal after 24 weeks treatment. It was found that sitagliptin in combination with metformin signifi cantly reduced the post-meal glycemia in association with enhancement of postmeal insulin and C-peptide levels as well as the determination of insulin secretion by calculating the postmeal insulin to glucose ratio, all in comparison with treatment with metformin alone.
Islet function when DPP-4 inhibition and metformin are used in initial combination therapy
In the study in which sitagliptin and metformin are given as initial combination ther apy (Goldstein et al 2007) , a standardized meal tolerance test was given after 24 weeks of treatment with analyses of glucose, insulin and C-peptide. It was found that along with the reduction in fasting glucose, the prandial glycemia was improved both by sitagliptin and metformin in monotherapy but an additive effect in reducing prandial glycemia was observed. Thus, the placebo-adjusted reduction in mean 2 h postmeal glucose was 6.5 mmol/l from the base line 2 hr glucose of 15.9 mmol/l in the subjects given sitagliptin 50 mg + metformin 1000 mg twice daily. Also insulin secretion, as determined by the AUC insulin divided by AUC glucose during the 2 hr postmeal period, was signifi cantly increased by the combina tion therapy in an additive manner versus monotherapy. Thus, the placebo-adjusted in crease in mean insulin secretion was 0.07 µU hr insulin/ml/mg h glucose/dl versus 0.16 at baseline, ie, an increase by 43%. The study also showed a signifi cant reduction in fasting proinsulin and in fasting proinsulin to insulin ratios after 24 weeks treatment with the combination of sitagliptin and metformin, again reinforcing an improved beta-cell function by this combination therapy. Furthermore, when calculating the insulin resistance index, HOMA-IR, a marked improvement in insulin sensitivity was seen by the combination; the placebo-adjusted value of HOMA-IR was reduced by 2.7 from a baseline of 6.2, ie, by 41%.
To summarize, the mechanistic studies of combination treatment with DPP-4 inhibition and metformin show increased GLP-1 levels and increased insulin secretion and insulin sensitivity. Nevertheless, more studies are required to fully understand the benefi ts of this combination, including effects on glucagon secretion. (Garber et al 2007; Rosenstock et al 2006; Rosenstock et al 2007) and insulin (Fonseca et al 2007) . This novel strategy to treat type 2 diabetes is expected to be of increasing value in the future treatment of type 2 diabetes. The overall experience is that this novel strategy is effi cient, highly tolerable and safe with a minimal risk for hypoglycemic events. A promising place in therapy for DPP-4 inhibition is in combination with metformin. This has been demonstrated in large studies with vildagliptin and sitagliptin, since these studies have shown that HbA 1c is reduced by 0.65%-1.1% from baseline levels of 7.8%-8.4% in studies up to 52 weeks. This improvement in glycemic control is similar as in studies with sulphonylureas, thizolidinediones or exenatide when added to metformin treatment. Furthermore, DPP-4 inhibition in combina tion with metformin is safe and tolerable. Hence, a major indication for treatment with DPP-4 inhibition as add-on to metformin in subjects inadequately controlled with metformin and as fi rst-line treatment in initial combination therapy with metformin. For future studies, the durability of effects of the combination of DPP-4 inhibition with metformin needs to be explored as well as more detailed mechanistic studies need to be undertaken, with particular to studies on glucagon secretion, prandial lipid levels and insulin sensitivity.
